PDCD6

Programmed cell death protein 6 · O75340 · PDCD6 on Sugi Atlas →

0 patent compounds predicted against PDCD6, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to PDCD6 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
co Ihibtory Receptor in Preeclampsia PHASE4UNKNOWN
Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria PHASE4RECRUITING
Effect of Tramadol Versus Morphine on PD1 and PD1-ligand in Patients With Chronic Cancer Pain PHASE2/PHASE3UNKNOWN
PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural Mesothelioma PHASE3COMPLETED
Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204) PHASE3COMPLETED
Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma (PICH Study) PHASE1/PHASE2WITHDRAWN
Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma PHASE2RECRUITING
Pembrolizumab (MK-3475) in MM Patients With Residual Disease PHASE2COMPLETED
Pembrolizumab And Tamoxifen Among Women With Advanced Hormone Receptor Positive Breast Cancer And Esr1 Mutation PHASE2UNKNOWN
Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer PHASE2RECRUITING
Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007) PHASE2COMPLETED
Tislelizumab Combined With Chemotherapy in the Treatment of Bone Metastases of Unknown Primary PHASE2UNKNOWN
Trimodal Therapy Plus Atezolizumab in Muscle-invasive Bladder Cancer PHASE2UNKNOWN
Study of Pembrolizumab in Combination With Chemotherapy for Patients With Advanced Colorectal Cancer PHASE2COMPLETED
Neoadjuvant Anti PD-1 Immunotherapy in Resectable Non-small Cell Lung Cancer PHASE2COMPLETED
Trimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer PHASE2ACTIVE_NOT_RECRUITING
Patients With ES-SCLC and ECOG PS=2 Receiving Atezolizumab-Carboplatin-Etoposide PHASE2COMPLETED
Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease PHASE2COMPLETED
A Multicentre Phase II Trial of Durvalumab Versus Physician's Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinomas PHASE2UNKNOWN
Study on the Safety and Tolerability of PD-1 Knockout Tumor-infiltrating T Cells (TILs) in the Treatment of Advanced Colorectal Cancer PHASE1RECRUITING
COLONYVAQ™, a Quantum-Classical Guided Personalized Neoantigen Vaccine for MSS Stage III Colorectal Cancer EARLY_PHASE1RECRUITING
Effect of Severe Trauma on PD1 and Its Legend (PD1/L1) on T Lymphocytes and Correlation With Mortality nanUNKNOWN
Role of Programmed Death Ligand 1 in Colorectal Cancer nanNOT_YET_RECRUITING
Effect of Anesthesia on Expression of Programmed Death-1 and Programmed Death-1 Ligand in Breast Cancer nanUNKNOWN
Modulatory Effect of Prodigiosin or Pioglitazone on TIME and the Crosstalk to Immune-Checkpoint Protein(s) nanNOT_YET_RECRUITING
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma nanCOMPLETED
Soluble Programmed Death 1 (sPD1) is a Diagnostic Biomarker of ILD in Patients With Rheumatoid Arthritis Disease nanUNKNOWN
Treatment With Immunological Checkpoint Inhibitors of HIV-infected Subjects With Cancer nanCOMPLETED
Correlation Between Specific Gene Mutationand Local Immune Microenvironment and Immunotherapy Efficacy in NSCLC nanUNKNOWN
Immuno-Oncology Database and Bioregistry nanACTIVE_NOT_RECRUITING

Related proteins — ESM-2 sequence neighbours (a PDCD6 binder may also engage these)

ProteinNameSimilarity
P12815 1.000 P12815 →
G3V7W1 1.000 G3V7W1 →
Q95YL5 0.988 Q95YL5 →
Q94743 0.983 Q94743 →
Q5PQ53 0.982 Q5PQ53 →
Q6DC93 0.980 Q6DC93 →
Q01449 0.979 Q01449 →
P07461 0.977 P07461 →
Q3THE2 0.977 Q3THE2 →
F1SSF9 0.976 F1SSF9 →
P24032 0.976 P24032 →
P97457 0.976 P97457 →
Q95YL4 0.976 Q95YL4 →
Q8BFY6 0.976 Q8BFY6 →
Q5RC34 0.975 Q5RC34 →
PEF1 Peflin 0.975 landscape →
A4IF97 0.975 A4IF97 →
Q27178 0.975 Q27178 →
P06815 0.975 P06815 →
Q9CQ19 0.975 Q9CQ19 →
P40423 0.974 P40423 →
P02612 0.974 P02612 →
Q3SEK0 0.974 Q3SEK0 →
Q9UUG5 0.974 Q9UUG5 →
Q641Z8 0.974 Q641Z8 →
Q94726 0.974 Q94726 →
Q9ZQH1 0.973 Q9ZQH1 →
Q9WVK4 0.973 Q9WVK4 →
Q10131 0.973 Q10131 →
Q5E9R3 0.973 Q5E9R3 →